UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): October 12, 2006
VioQuest
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
000-16686
|
58-1486040
|
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
180
Mt. Airy Road, Suite 203
Basking
Ridge, NJ 07920
(Address
of principal executive offices)
(908)
766-4400
(Registrant's
telephone number, including area code)
________________________________________
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers.
|
Effective
October 13, 2006, Dr. Lawrence Akinsanmi, M.D., Ph.D., who joined VioQuest
Pharmaceuticals, Inc. (the “Company”) on October 1, 2006, will assume the
responsibilities of Dr. Pamela Harris, the Company’s former Chief Medical
Officer, who resigned from her employment with the Company on October 12, 2006.
Dr. Akinsanmi will retain the title of Vice President of Clinical Operations
and
Regulatory Affairs.
Prior
to
joining the Company, Dr. Akinsanmi served as global lead, early development
and
senior director of regulatory affairs at Daiichi Medical research, Inc., from
January 2004 to September 2006. From January 2002 to December 2003, he served
as
Senior Director, Regulatory & Medical Affairs at Omnicare Clinical Research.
From February 1997 to October 2001, Dr. Akinsamni was employed by Immunomedics,
Inc., where he served as its Director of Regulatory and Medical Affairs. Dr.
Akinsamni has also held various clinical research positions at academic and
commercial research organizations. Dr. Akinsanmi’s prior experiences include
preparing and supporting IND and NDA filings with the Food and Drug
Administration and foreign regulatory authorities, and he has also been involved
in several oncology drug development projects. Dr. Akinsanmi also has broad
oncologic drug development knowledge, and has previously worked on several
cancer products at various stages of development, including LymphoCide®,
CeaCide®, Iressa®, Satraplatin®, Camptosar® and Oral Taxane®. Dr. Akinsanmi also
possesses expertise in the area of infectious diseases, having previously worked
on Leishmaniasis.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
VIOQUEST PHARMACEUTICALS,
INC.
|
|
|
|
| Date: October
13, 2006 |
By: |
/s/
Brian
Lenz |
| |
Brian
Lenz
Chief
Financial Officer
|
| |
|